New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
08:01 EDTHALOHalozyme upgraded to Buy from Neutral at UBS
UBS transitioned coverage on Halozyme with a Buy rating from a Neutral rating. The firm upgraded shares due to valuation and is more bullish on the PEGPH20 program following the recently removed clinical hold and believes the Herceptin-SC launch is tracking well and provides near-term support and strong uptake. Price target raised to $16 from $%14.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 22, 2015
07:45 EDTHALOHalozyme price target raised to $25 from $20 at JPMorgan
JPMorgan raised its price target for Halozyme to $25 after speaking with CEO Hellen Torley. The firm remains positive on the potential for PEGPH20 and keeps an Overweight rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use